Susan Moran

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 398 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +11

Social Smoking Among US College Students

Susan Moran, Henry Wechsler, Nancy A. Rigotti · PEDIATRICS · 2004 · 262 citations

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Alasdair Coles, Edward Fox, Anton Vladić et al. · Neurology · 2012 · 260 citations

US College Students’ Exposure to Tobacco Promotions: Prevalence and Association With Tobacco Use

Nancy A. Rigotti, Susan Moran, Henry Wechsler · American Journal of Public Health · 2005 · 162 citations · Full text